In 1987, we studied the prevalence of asthma and rhinoconjunctivitis in 1112 grade-eight students in the town of Umeå, northern Sweden. The present study is based on the same cohort, reinvestigated in 1991. We aimed to estimate the changes in the prevalence of asthma and rhinoconjunctivitis and to examine some presumed risk factors of asthma and rhinoconjunctivitis. A postal questionnaire on present asthma, rhinoconjunctivitis, symptoms from the upper and lower airways, and the need for medication was used. Questions about living conditions, smoking, and present education were also included. The questionnaire was answered by 89% (990) of the subjects. The prevalence of self-reported asthma was 10.8% (boys 7.9%, girls 13.7%). The incidence rate/year was 1.1%, the remission rate/year was 5.7%, and the relapse rate/year was 10%. The risk factors for developing asthma appeared to be atopy, having a family history of asthma or rhinoconjunctivitis, and smoking. The prevalence of self-reported rhinoconjunctivitis was 14.3% (boys 15.6%, girls 13.1%). The incidence rate/year was 1%, the remission rate/year was 22%, and the relapse rate/year was 11%. Stopping smoking and having no family history of rhinoconjunctivitis or asthma appeared to favor remission in rhinoconjunctivitis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1398-9995.1998.tb03770.x | DOI Listing |
J Investig Allergol Clin Immunol
January 2025
Section of Occupational Medicine, Respiratory Diseases and Toxicology, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
Inflamm Intest Dis
January 2025
University Center for Gastrointestinal and Liver Diseases, Clarunis, Basel, Switzerland.
Background: Eosinophilic esophagitis (EoE) has been described as a chronic allergen/immune-mediated disease characterized by symptoms of esophageal dysfunction and eosinophilic infiltration of the mucosa.
Summary: Over the past decades, EoE has been increasingly recognized in various geographical areas with a high socioeconomic development (mostly industrialized countries) and has evolved from an unknown to a clinically distinct disease with increasing prevalence and incidence. An average age at diagnosis between 30 and 50 years and a male predominance have been consistently observed.
J Allergy Clin Immunol
January 2025
Departments of Pediatrics and Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wis.
Background: Rhinoconjunctivitis phenotypes are conventionally described on the basis of symptom severity, duration and seasonality, and aeroallergen sensitization. It is not known whether these phenotypes fully reflect the patterns of symptoms seen at a population level.
Objective: We sought to identify phenotypes of rhinoconjunctivitis on the basis of symptom intensity and seasonality using an unbiased approach and to compare their characteristics.
Scand J Prim Health Care
December 2024
The Research Unit for General Practice in Slagelse, Køge and Copenhagen, and Section of General Practice, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
Introduction: Atopic dermatitis (AD) and related atopic diseases are among the chronic health conditions that are becoming more common in children. Children with AD may develop atopic comorbidities, which makes it more difficult to manage treatment and necessitates more precautions in the child's everyday life. The parents of chronically ill children play a key role as the children's primary carers.
View Article and Find Full Text PDFImmun Inflamm Dis
December 2024
Medical Affairs and Clinical Department, LETI Pharma S.L.U., Madrid, Spain.
Background: Efficacy of allergen immunotherapy is dose-dependent; however, high doses of allergen may imply a greater risk of adverse reactions.
Objective: To assess the safety and tolerability of subcutaneous immunotherapy (SCIT) with mixtures of mite allergen extracts, Dermatophagoides pteronyssinus/Blomia tropicalis (Dpt/Bt) and Dermatophagoides pteronyssinus/Lepidoglyphus destructor (Dpt/Ld) at maximum concentrations, in adult patients with allergic rhinitis or rhinoconjunctivitis, and controlled allergic asthma due to a clinically relevant sensitisation to these mites.
Methods: An open-label, noncontrolled, nonrandomised, phase IIb clinical trial was carried out in three hospitals in Spain between September 2014 and May 2018.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!